losartan has been researched along with Granulocytic Leukemia, Chronic in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schoepf, AM | 1 |
| Salcher, S | 1 |
| Obexer, P | 1 |
| Gust, R | 1 |
| Zaki, KS | 1 |
| Majid, U | 1 |
| Islam, N | 1 |
2 other studies available for losartan and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARĪ³ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistan | 2020 |
Spurious hyperkalaemia: an insight.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Chemical Analysis; False Positive Reactions; Fe | 2011 |